ACAndrew L. Chan

Andrew L. Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew L. Chan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A review of current and novel therapies for idiopathic pulmonary fibrosis

    by Rokhsara Rafii, Maya M. Juarez, Timothy E. Albertson, Andrew L. Chan

    A review of current and novel therapies for idiopathic pulmonary fibrosis


  • Open Access

    Novel computed tomographic chest metrics to detect pulmonary hypertension

    by Andrew L Chan, Maya M Juarez, David K Shelton, Taylor MacDonald, Chin-Shang Li, Tzu-Chun Lin, Timothy E Albertson

    Early diagnosis of pulmonary hypertension (PH) can potentially improve survival and quality of life. Detecting PH using echocardiography is often insensitive in subjects with lung fibrosis or hyperinflation. Right heart catheterization (RHC) for the diagnosis of PH adds risk and expense due to its invasive nature. Pre-defined measurements utilizing computed tomography (CT) of the chest may be an alternative non-invasive method of detecting PH.


  • Open Access

    Do airway metallic stents for benign lesions confer too costly a benefit?

    by Andrew L Chan, Maya M Juarez, Roblee P Allen, Timothy E Albertson

    The use of self-expanding metallic stents (SEMAS) in the treatment benign airway obstruction is controversial.


  • Pharmacokinetics and clinical effects of mono‐l‐aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces

    by Andrew L. Chan, Maya Juarez, Roblee Allen, William Volz, Timothy Albertson

    Background/Purpose: Mono‐l‐aspartyl chlorin e6 (NPe6) is a photosensitizer that exhibits chemical purity, absorption at 664 nm wavelength and may be useful in photodynamic therapy (PDT).Methods: This open label phase I clinical trial at the University of California, Davis Medical Center examined the pharmacokinetic properties of Npe6 and clinical response to PDT with this photosensitizer. A single intravenous dose of Npe6 was administered to 14 cancer patients with superficial malignancies (basal cell carcinoma=22 lesions, squamous cell cancer=13 lesions, papillary carcinoma=14 lesions). Patients received one of five ascending doses (0.5 mg/kg (n=4), 1.0 mg/kg (n=3), 1.65 mg/kg (n=3), 2.5 mg/kg (n=3), or 3.5 mg/kg (n=1)) 4–8 h prior to light activation. The total light dose (range 25–200 J/cm2) depended on the tumor shape and size. Light was delivered using an argon‐pumped tunable dye laser. Serum NPe6 concentrations were measured over a 28‐day period. The toxicity and cutaneous clinical efficacy of NPe6 were observed.Results: Four weeks post‐PDT, 20 of 22 basal cell carcinoma tumors (91%) showed a complete response. Eighteen of 27 other malignant cutaneous tumors showed a complete (n=15/27, 56%) or partial (n=3/27, 11%) response. Fewer non‐responders were seen at an Npe6 dose level of 1.65 mg/kg or higher. Only 2 of 14 patients experienced an adverse event that was definitely related to NPe6 administration. Photosensitivity resolved within 1 week of NPe6 dosing in 12 of 14 patients. Analysis of serum levels of 11 individual patients indicated that a two‐compartment model with a residual phase best fits the data. The mean α, β, and terminal half‐lives were 8.63±2.92, 105.90±37.59 and 168.11±53.40 h (±1 SD), respectively. The observed mean volume of distribution was 5.94±2.55 l, and the mean clearance was 0.0394±0.0132 l/h. These values were independent of the dose administered.Conclusion: The photosensitizer, NPe6, was well tolerated with minimal phototoxic side effects, and demonstrated preliminary efficacy against cutaneous malignancies.


  • Lymphangioleiomyomatosis and SZ α1-Antitrypsin Disease*

    by Andrew L. Chan, Sunye Kwack, Kirk D. Jones, Marilyn K. Glassberg, Charles R. Gherman


  • Advances in the management of endobronchial lung malignancies

    by Andrew L. Chan, Ken Y. Yoneda, Roblee P. Allen, Timothy E. Albertson

    The effective palliation of endobronchial malignancies often involves the use of multiple modalities including surgery, external beam radiation, chemotherapy, or a variety of interventional bronchoscopic techniques. The authors discuss in detail recent advances in interventional bronchoscopy that enhance local tumor control. An integrated and individualized approach to the use of these complementary modalities can provide rapid palliation and may improve survival in a subset of patients.


  • Bronchoscopic Management of an Endobronchial Primary Paraganglioma

    by Samuel J. Evans, Roblee P. Allen, Shawn S. Aghili, Andrew L. MB Chan

    Primary pulmonary paraganglioma is an extremely rare entity. Less than 20 cases have been reported in the English literature and little is known about the natural history, optimal management, and ultimate prognosis of this disease. Paragangliomas are thought to arise from neuroendocrine chemoreceptors and are most commonly discovered in the head and neck and retroperitoneal regions. Anecdotal case reports in the literature include presentations that vary from asymptomatic, incidental solitary nodules to metastatic, catecholamineproducing lesions. Pulmonary paragangliomas are often located in the intraparenchymal or subpleural spaces. There is little literature regarding the local management of endobronchial paragangliomas. We report a case of a 54-year-old woman presenting with a history of shortness of breath, hemoptysis, and chest pain who was found to have a large endobronchial paraganglioma completely obstructing her distal trachea and left mainstem bronchus. She underwent Nd:YAG laser phototherapy with subsequent stent placement. These interventional bronchoscopic techniques successfully relieved her obstruction and allowed rapid weaning from mechanical ventilation.

  • Obstructive Sarcoidosis

    by Petey Laohaburanakit, Andrew Chan

    Sarcoidosis is a systemic granulomatous disease that frequently involves the lung. Although classically thought of as a restrictive lung disease, airway obstruction has become a recognized feature of the disease in the past years. Sarcoidosis can affect the airway at any level and when the involvement includes small airways, it can resemble more common obstructive airway diseases, such as asthma and chronic bronchitis. Pulmonary function testing and high-resolution computerized tomography of the chest are two important tools to evaluate the presence and extent of airway obstruction in sarcoidosis. Pharmacologic options for the treatment of obstructive sarcoidosis are, in large part, not supported by large randomized clinical trials. In severe cases of bronchostenosis owing to sarcoidosis granuloma or extrinsic compression from intrathoracic lymphadenopathy, interventional bronchoscopy has successfully been performed, although repeated procedures are usually required. Lung transplantation is an ultimate option in selected patients with late-stage fibrotic disease.


  • Unusual primary lung neoplasms

    by Andrew L. Chan, David K. Shelton, Ken Y. Yoneda

    Bronchial carcinoids and hamartomas are, respectively, the most common malignant and benign unusual primary lung neoplasms. These tumors are often asymptomatic but can cause central airway obstruction. Helical computed tomographic and radionuclide scintigraphic advances in their detection and evolution, together with newer interventional bronchoscopy techniques such as neodymium:yttrium-aluminum-garnet laser phototherapy and cryotherapy, represent important improvements in the diagnosis and management of patients with such tumors.